- Exchange: EN Paris
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Ipsen SA (IPN)
| Open: | 20.4000 | Day's Range: | 20.4000 - 20.8500 | Volume: | 50,398 | Bid: | 20.7300 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 20.3050 | 52wk Range: | 18.2600 - 28.7500 | 1-Yr Rtn: | -25.05% | Ask: | 20.8050 |
Key Statistics for IPN
| Current P/E Ratio (ttm) | 5,063.4765 |
|---|---|
| Estimated P/E (12/2012) | 13.1017 |
| Earnings Per Share (EUR) (ttm) | 0.0041 |
| Est. EPS (EUR) (12/2012) | 1.5830 |
| Est. PEG Ratio | 1.4525 |
| Market Cap (M EUR) | 1,746.86 |
| Shares Outstanding (M) | 84.23 |
| Enterprise Value (M EUR) (ttm) | 1,630.19 |
| Enterprise Value/EBITDA (ttm) | 6.71 |
| Price/Book (mrq) | 1.7244 |
| Price/Sale (ttm) | 1.5104 |
| Dividend Indicated Gross Yield | 3.8573 |
| Next Earnings Announcement | 08/28/2012 |
More IPN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for IPN
- Operating
- Investing
- Financing (M/EUR)
Company Profile & Key Executives for IPN
Ipsen SA manufactures and markets a wide range of medical drugs for targeted disease areas including oncology, endocrinology, and neuromuscular disorders.
| Marc De GaridelChairman/CEO | Susheel SurpalExec VP/CFO |
| Nathalie JoannesExec VP/General Counsel | Claude BertrandExec VP:Research & Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page